|
Market Closed -
Nasdaq
21:00:00 10/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.1852 USD | +1.98% |
|
-2.01% | -81.48% |
| 10-16 | Tscan Therapeutics, Inc. Announces Board and Committee Changes, Effective October 13, 2026 | CI |
| 09-30 | TScan Therapeutics, Inc. Announces Departure of Chrystal Louis as Chief Medical Officer | CI |
Company Valuation: TScan Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 106.9 | 37.32 | 278.8 | 171.8 | 56.75 | 12.55 | - | - |
| Change | - | -65.09% | 647.03% | -38.39% | -66.96% | -77.88% | - | - |
| Enterprise Value (EV) | -54.48 | -53.41 | 116.8 | -86.26 | -63.12 | 12.55 | 12.55 | 12.55 |
| Change | - | 1.96% | 318.71% | -173.84% | 26.82% | 119.89% | 0% | 0% |
| P/E | -1.08x | -0.56x | -4.29x | -2.67x | -1x | -0.23x | -0.31x | -0.32x |
| PBR | - | 0.37x | 1.85x | 0.71x | 0.46x | - | - | - |
| PEG | - | 0x | 0.1x | 0.2x | 0.1x | 0x | 0x | 0.1x |
| Capitalization / Revenue | 10.5x | 2.76x | 13.2x | 61x | 5.5x | 4.3x | 10x | 1.34x |
| EV / Revenue | -0x | -0x | 0x | -0x | -0x | 4.3x | 10x | 1.34x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | 0x | -0x | 0x | 0x | -0.12x | -0.16x | -0.14x |
| EV / FCF | 0x | 0x | -0x | 0x | 0x | -0.22x | -0.32x | -0.36x |
| FCF Yield | -54.8% | -190% | -23.1% | -66.7% | -246% | -449% | -308% | -276% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -4.17 | -2.75 | -1.36 | -1.14 | -1 | -0.805 | -0.6 | -0.58 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.14 | 13.54 | 21.05 | 2.816 | 10.32 | 2.921 | 1.25 | 9.4 |
| EBITDA | -42.8 | -56.95 | -82.89 | -121.2 | -121.2 | - | - | - |
| EBIT 1 | -48.64 | -66.64 | -93.46 | -134.8 | -135.8 | -106.5 | -77.07 | -87.79 |
| Net income 1 | -48.62 | -66.22 | -89.22 | -127.5 | -129.8 | -104.9 | -79.1 | -86.94 |
| Net Debt | -161.4 | -90.74 | -162 | -258 | -119.9 | - | - | - |
| Reference price 2 | 4.5000 | 1.5500 | 5.8300 | 3.0400 | 1.0000 | 0.1852 | 0.1852 | 0.1852 |
| Nbr of stocks (in thousands) | 23,761 | 24,080 | 47,825 | 56,505 | 56,748 | 67,779 | - | - |
| Announcement Date | 09/03/22 | 08/03/23 | 06/03/24 | 05/03/25 | 04/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.23x | - | - | - | 12.55M | |
| 17.83x | 6.86x | 13.15x | 1.67% | 68.32B | |
| 32.59x | 8.71x | 28.8x | 0.07% | 60.26B | |
| 38.31x | 6.82x | 20.38x | 0.85% | 55.86B | |
| 47.19x | 6.4x | 30.36x | -.--% | 48.43B | |
| 35.91x | 3.38x | 14.61x | -.--% | 45.34B | |
| -23.04x | 61.61x | -25.45x | -.--% | 41.76B | |
| 34.38x | 8.51x | 22.17x | 0.38% | 34.5B | |
| 41.76x | 8.19x | 27.2x | -.--% | 33.8B | |
| 30.01x | 6.36x | 16.49x | -.--% | 25.96B | |
| Average | 25.47x | 12.98x | 16.41x | 0.33% | 41B | |
| Weighted average by Cap. | 28.12x | 12.42x | 16.79x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TCRX Stock
- Valuation TScan Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
